The type of small-vessel disease in small deep (lacunar) infarcts (SDIs) remains contentious as opposed to that in primary intracerebral haemorrhage (PICH), which is lipohyalinosis in most cases. Therefore, we compared risk factor profiles as indicators of underlying vessel pathology, between patients with SDI and patients with PICH, and those with a non-cardio-embolic infarct involving the cortex (CORTI). Multivariate regression analysis showed that diabetes mellitus [odds ratio (OR) 0.56; 95% confidence interval (CI) 0.34–0.90] and hypercholesterolaemia (OR 0.63; 95% CI 0.40–0.99) were more strongly associated with CORTI than with SDI. Carotid stenosis was associated with SDI in comparison with PICH (OR 7.5; 95% CI 1.02–54.94). Compared with PICH, CORTI was more strongly associated with diabetes mellitus (OR 3.27; 95% CI 1.38–7.76), carotid stenosis (OR 24.42; 95% CI 4.99–119.45), and hypercholesterolaemia (OR 3.12; 95% CI 1.47–6.65), whereas hypertension was associated with PICH (OR 0.37; 95% CI 0.18–0.79). These data support the hypothesis that small-vessel atheromatosis rather than small-vessel lipohyalinosis underlies lacunar infarcts in most cases.

Keywords:
Small deep infarct, Lacunar stroke, Cerebral haemorrhage, Lipohyalinosis, Hypertension, Small-vessel disease
1.
Lodder J, Bamford J, Sandercock P, Jones L, Warlow C: Are hypertension or cardiac embolism likely causes of lacunar infarction? Stroke 1990;21:375–381.
2.
Boiten J, Lodder J: Lacunar infarcts. Pathogenesis and validity of the clinical syndromes. Stroke 1991;22:1374–1378.
3.
Boiten J, Lodder J, Kessels F: Two clinically distinct lacunar infarct entities? Stroke 1993;5:652–656.
4.
You R, McNeil JJ, O’Malley HM, Davis SM, Donnan GA: Risk factors for lacunar infarct syndromes. Neurology 1995;45:1483–1487.
5.
van Zagten M, Lodder J, Franke C, Heuts-van Raak L, Claassens C, Kessels F: Different vascular risk factor profiles in primary intracerebral haemorrhage and small deep infarct do not suggest similar types of underlying small vessel disease. Cerebrovasc Dis 1994;4:121–124.
6.
Marini C, Di Napoli M, Di Gianfilippo G, Santalucia P, Baldassarre M, De Matteis G, di Orio F, Carolei A: L’Aquila Stroke Registry: First-year results. Eur J Neurol 1995;(suppl 2):13.
7.
Bogousslavsky J, van Melle G, Regli F: The Lausanne Stroke Registry: Analysis of 1,000 consecutive patients with first ever stroke. Stroke 1988;9:1083–1093.
8.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: A prospective study of cerebrovascular disease in the community: The Oxfordshire Stroke Project 1981–86. J Neurol Neurosurg Psychiatry 1990;53:16–22.
9.
Feldmann E: Intracerebral haemorrhage. Stroke 1991;22:684–691.
10.
Luijckx GJ, Boiten J, Lodder J: Is the vasculopathy underlying symptomatic lacunar stroke part of a generalised small vessel disease? (abstract). Cerebrovasc Dis 1995;5:232.
11.
Janssens E, Mounier-Veheir F, Hamon M, Leys D: Small subcortical infarcts and primary subcortical haemorrhages may have different risk factors. J Neurol 1995;242:425–429.
12.
Bogousslavsky J, Castillo V, Kumral E, Henriques I, Van Melle G: Stroke subtypes and hypertension. Primary hemorrhage vs infarction, large- vs small-artery disease. Arch Neurol 1996;53:265–269.
13.
van Zagten M, Boiten J, Kessels F, Lodder J: The extent of white matter lesions and the number of small deep infarcts on CT significantly progress over time in stroke patients. Arch Neurol 1996;53:650–655.
14.
Bamford J, Sandercock P, Jones L, Warlow C: The natural history of lacunar infarction: The Oxfordshire Community Stroke Project. Stroke 1987;18:545–551.
15.
Guidelines Sub-Committee of the WHO/ISM Mild Hypertension Liaison Committee: 1993 guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993;11:905–918.
16.
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–1057.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.